The Federal Trade Commission (FTC) recently turned its attention to a number of pharmaceutical companies, raising concerns about potential faulty patents listed in a crucial federal drug database. Among the companies caught in this scrutiny are the makers of Ozempic, a widely used diabetes and weight loss drug.
This move forms part of an ongoing FTC endeavour, where the regulatory body continues to seek out what it perceives to be ‘junk’ drug patents, highlighting possible weaknesses in the patent listing system. These potential faulty patents, and their ramifications for both regulators and the broader pharmaceutical industry, act to illustrate the complex nature of the federal drug database and its crucial role in oversight.
Discover more about this issue in Adam Lidgett’s article on Law360.